OncLive® On Air

S16 Ep12: Evolving Standards and Emerging ADCs Redefine Cervical Cancer Care: With Ursula A. Matulonis, MD; and Susana M. Campos, MD, MPH

S16 Ep11: Treatment Evolutions Affect First-Line Chemotherapy Selection in Metastatic Pancreatic Cancer: With Rachna T. Shroff, MD, MS, FASCO; and Kristen Spencer, DO

Metastatic pancreatic cancer management centers on balancing life-prolonging efficacy with the preservation of quality of life, as current treatments remain palliative. Clinicians prioritize aligning therapeutic choices with patient goals, symptom burden, and performance status while integrating supportive care early i...

S16 Ep10: Optimizing TKI Sequencing and Ponatinib Dosing Strategies in CML: With Quinto Gesiotto, MD

S16 Ep9: A Thoracic Oncologist’s Journey from Iran to Innovation: With Girindra Raval, MD; and Hossein Borghaei, DO, MS

S16 Ep8: ASCO GU 2026 Preview

S16 Ep7: Answering Common Questions About Chondrosarcoma Diagnosis and Management: With Hari Desphande, MD, and Philippos Costa, MD

S16 Ep6: FDA Approval Insights: Subcutaneous Amivantamab for EGFR-Mutated NSCLC: With Alexander I. Spira, MD, PhD, FACP, FASCO

S16 Ep5: Cases & Conversations™: Unmasking Epithelioid Sarcoma – Enhancing Early Diagnosis and Multidisciplinary Care

S16 Ep4: Comprehensive Ph+ ALL Paradigm Knowledge Informs Frontline Ponatinib Use: With Nicholas Short, MD

S16 Ep3: Third-Line Treatment Selection in mCRC Is Shaped By Recalibration of Patient Priorities and Molecular Retesting: With Christopher Lieu, MD

S16 Ep2: “D” is for Diagnosis: Decoding a Difficult Thoracic Malignancy—Piecing Together a Rare Diagnosis, Preparing for Tomorrow’s Treatments

S16 Ep1: Targeted Therapies Take Center Stage for Estrogen Receptor–Positive Breast Cancer: With Aditya Bardia, MD, MPH, FASCO

Aditya Bardia, MD, MPH, FASCO, evaluates the shifting treatment landscape for HR-positive, HER2-negative breast cancer, highlighting the Phase III lidERA study results. This trial demonstrates that the novel oral selective estrogen receptor degrader (SERD) giredestrant reduces the risk of recurrence or death by 30% com...

S15 Ep50: Bladder Cancer Experts Note Implications of Upfront Enfortumab Vedotin Dose Reduction in Advanced Urothelial Carcinoma: With Ramy Sedhom, MD; Ryan Chow, MD; and Ronac Mamtani, MD, MSCE

S15 Ep49: Innovation, Equity, and the Future of Oncology: World Cancer Day Spotlight With Deb Schrag, MD, MPH

S15 Ep48: Multidisciplinary Teams Optimize Surgical and Therapeutic Roles in Advanced CSCC Care: With Eric Whitman, MD; and Vishal Patel, MD, FAAD, FACMS

S15 Ep47: ASCENT-07 Trial Propels Further Questions About the Role of Earlier-Line ADCs in HR+ Metastatic Breast Cancer: With Komal Jhaveri, MD, FACP

S15 Ep46: Expanded BTK Inhibitor Research Directs the Evolution of Pirtobrutinib Use in CLL: With Andrew Lipsky, MD

S15 Ep45: Early, Reflex Biomarker Testing Is Critical to Optimizing NSCLC Treatment Decisions Across Disease Stages: With Adam Fox, MD, and Cynthia A. Schandl, MD, PhD

S15 Ep44: Subcutaneous Isatuximab via On-Body Injector Has Noninferior Efficacy vs IV Delivery in Myeloma: With Sikander Ailawadhi, MD; and Beth Faiman, CNP, PhD

S15 Ep43: Medical Crossfire®: The Who, When, and How of TROP2-Targeting ADCs, ICIs, and PARP Inhibition in Triple-Negative Breast Cancer